Clinical Trials: Pancreatic Cancer

Alabama

Mobile; University of South Alabama, Mitchell Cancer Institute
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Mobile; University of South Alabama
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Arizona

Scottsdale; Mayo Clinic Arizona
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Tucson; University of Arizona, Arizona Cancer Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Arkansas

Hot Springs; Genesis Cancer Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

California

Duarte; City of Hope
PaTK01: A Phase I Study of ADV-TK Therapy in Combination with Surgery and Chemoradiation for Pancreas

Duarte; City of Hope
Procurement and Research Evaluation of Human Blood and Tissues for Detection of Occult Malignancies Using the Polymerase Chain Reaction (PRCR)

Duarte; City of Hope
CA180114: A Phase II Clinical Trial of Dasatinib in Patients with Metastatic Pancreatic Cancer

Glendale; Glensdale Adventist Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

La Jolla; University of California San Diego, Moores Cancer Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Los Angeles; Norris Comprehensive Cancer Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Los Angeles; UCLA Department of Medicine
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Los Angeles; USC/Norris Comprehensive Cancer Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Mobile; University of South Alabama - Mitchell Cancer Institute
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Orange; UC Irvine Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Orange; University of California/Irvine Medical Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Rancho Mirage; Desert Hematology Oncology Medical Group, Inc.
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Rancho Mirage; Desert Hematology Oncology Medical Group, Inc.
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

San Diego; Scripps Cancer Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

San Francisco; San Francisco General Hospital
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Tampa; University of South Florida - Digestive Disorders Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Colorado

Denver; University of Colorado Health Science Center Facility
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Florida

Boca Raton; The Center for Hematology-Oncology
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Boca Raton; The Center for Hematology-Oncology
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Jacksonville; Mayo Clinic Jacksonville
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Miami; University Of Miami
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Tampa; H. Lee Moffitt Cancer Center & Research Institute
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Tampa; Tampa General Hospital
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Tampa; University of South Florida
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

West Palm Beach; Palm Beach Cancer Institute
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Georgia

Atlanta; Winship Cancer Center, Emory University
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Idaho

Pocatello; Portneuf Cancer Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Illinois

Chicago; Chicago, Illinoise, University of Chicago Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Evanston; Evanston Northwestern Healthcare
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Olympia Fields; St. James Hospital and Health Centers Comprehensive Cancer Institute
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Olympia Fields; St James Hospital and Health Centers
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Peoria; Oncology Hematology Associates of Central Illinois, PC
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Peoria; Oncology Hematology Associates of Central Illinois, PC
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Indiana

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase II; First Line Treatment

Indianapolis; Indiana University Medical Goup
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Iowa

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Kentucky

Lexington; University of Kentucky Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Louisiana

Covington; Hematology and Oncology Specialists, LLC
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Metairie; Hematology and Oncology Specialists, LLC
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Metairie; Hematology and Oncology Specialists, LLC
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Maryland

Baltimore; Johns Hopkins Medical Center, Sidney Kimmell Comprehensive Cancer Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Massachusetts

Boston; Beth Isreal Deaconess Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Boston; The Neely for Clinical Cancer Research, Tufts New England Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Pittsfield; Berskhire Hematology Oncology PC
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Michigan

Ann Arbor; University Of Michigan
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Detroit; Wayne State University, Karmanos Cancer Institute
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Detroit; Karmanos Cancer Institute
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Minnesota

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Missouri

Columbia; Ellis Fischel Cancer Center
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

St. Louis; Washington University
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

St. Louis; Washington University in St. Louis School of Medicine
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Montana

Billings; Billings Clinic
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Billings; Billings Clinic
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Billings; Billings Clinic
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Billings; Billings Clinic
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Billings; Billings Clinic
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

New Hampshire

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

New Jersey

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

New York

New York; Columbia University Medical Center
A phase II, open-label, non-randomized, multicenter, single agent study of intravenous sdx-102 for the treatment of patients with MTAP - deficient cancers.

New York; Columbia University Medical Center
Phase I Study of CellCept (Mycophenolate Mofetil) for Advanced Pancreatic Cancer Phase

New York; Beth Israel Medical Center, BI Cancer Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

North Carolina

Charlotte; Carolinas Hematology Oncology Associates
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Charlotte; Carolinas Hematology Oncology Associates
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Greenville; Leo W. Jenkins Cancer Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Ohio

Canton; Gabrail Cancer Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Canton; Gabrail Cancer Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Cleveland; Cleveland Clinic Foundation
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Oregon

Portland; Portland Providence Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Portland; Legacy Clinical Research & Technology Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Pennsylvania

Philadelphia; Hospital of the University of Pennsylvania
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

South Carolina

Charleston; Charleston Cancer Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Greenville; Cancer Centers of the Carolinas
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Texas

Austin; Southwest Regional Cancer Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Dallas; Univeristy of Texas Southwestern Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Dallas; Mary Crowley Medical Research Center (MCMRC)Texas Oncology-Presbyrerian Hospital of Dallas
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Dallas; Mary Crowley Medical Research Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Dallas; Mary Crowley Medical Research Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Dallas; Mary Crowley Medical ResearchCenter (MCMRC)Texas Oncology-Presbyrerian Hospital of Dallas
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Dallas; Mary Crowley Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Dallas; Mary Crowley Medical Research Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Dallas; Texas Oncology, PS-Presbyrerian
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Pancreas

Houston; Oncology Consultants, PA
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Houston; Baylor College of Medicine
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Houston; Oncology Consultants, PA
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Houston; Elkins Pancreas Center
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Various Cities; Research Center
RADIANT-3: Advanced Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Study CRAD001C2324

Virginia

Richmond; Virginia Commonwealth University
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Washington

Seattle; Seattle Cca/Fred Hutchinson Cancer Research Ctr
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Seattle; Virginia Mason Medical Center
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Washington, DC

Washington; Georgetn Univ Lombardi Can Ctr
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Washington; MEDSTAR / Georgetown, MedStar Research Institute
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Wisconsin

Marshfield; Marshfield Clinic Research Foundation
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Milwaukee; University of Wisconsin, Division of Neoplastic Diseases & Related Disorders
A Randomized, Phase II/III, Study of TNFerade™ Biologic with 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer

International

Buenos Aires , Argentina; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Rosario, Argentina; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

San Martín, Argentina; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Santa Fe, Argentina; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Villa Domínico, Argentina; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Adelaide, Australia; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Adelaide, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Ballarat, Australia; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Brisbane, Australia; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Canberra, Australia; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Heidelberg, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Liverpool, Australia; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Melbourne, Australia; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Melbourne, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

St. Leonards, Australia; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

St. Leonards, Australia; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

St. Leonards, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Sydney, Australia; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Sydney, Australia; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Sydney, Australia; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Graz, Austria; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Innsbruck, Austria; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Salzburg, Austria; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Salzburg, Austria; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Wien, Austria; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Wien, Austria; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Antwerpen, Belgium; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Antwerpen, Belgium; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Bruxelles, Belgium; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Bruxelles, Belgium; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Gent, Belgium; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Leuven, Belgium; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Leuven, Belgium; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Liege, Belgium; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Wilrijk, Belgium; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Belo Horizonte, Brazil; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Belo Horizonte, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Curitiba - Pr, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Ijuí, Brazil; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Ijuí, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Jaú, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Porto Alegre, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Porto Alegre - Rs, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Porto Alegre Rs, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Salvador, Brazil; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Salvador, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Santo Andre, Brazil; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Sao Paulo, Brazil; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Sao Paulo, Brazil; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Gabrovo, Bulgaria; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Pleven, Bulgaria; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Plovdiv, Bulgaria; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Sofia, Bulgaria; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Varna, Bulgaria; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Vratza, Bulgaria; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Edmonton, AB, Canada; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Edmonton, AB, Canada; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Montreal, QC, Canada; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Ottawa, ON, Canada; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Quebec City, QC, Canada; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Toronto, ON, Canada; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Toronto, ON, Canada; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Vancouver, BC, Canada; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Beijing, China; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Hong Kong, China; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Hong Kong, China; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Shanghai, China; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Brno, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Hradec Kralove, Czech Republic; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Copenhagen Oe (Ø), Denmark; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Hillerød, Denmark; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Helsinki, Finland; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Angers, France; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Besancon, France; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Besancon, France; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Besancon, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Bordeaux, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Boulogne-Billancourt, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Brest, France; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Clichy, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Limoges, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Marseille, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Paris, France; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Paris, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Rouen, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Saint Herblain, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Saint Priest En Jarez, France; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Strasbourg, France; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Villejuif, France; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Berlin, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Berlin, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Bochum, Germany; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Bochum, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Bochum, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Bochum, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Bonn, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Bonn, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Dresden, Germany; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Esslingen, Germany; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Esslingen, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Esslingen, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Frankfurt Am Main, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Frankfurt Am Main, Germany; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Freiburg, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Halle, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Hamburg, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Hamburg, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Hamm, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Heidelberg, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Heidelberg, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Kaiserslautern, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Köln, Germany; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Leipzig, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Leipzig, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Magdeburg, Germany; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Magdeburg, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Mainz, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Mainz, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Mannheim, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Marburg, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

München, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

München, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Münchengladbach, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Münchengladbach, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Regensburg, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Saarbruecken, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Trier, Germany; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Trier, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Tübingen, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Ulm, Germany; Research Site:
A Study of Xeloda (Capecitabine) and Herceptin (Trastuzumab) in Patients With Advanced or Metastatic Pancreatic Cancer

Ulm, Germany; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Heraklion, Greece; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Thessaloniki, Greece; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Bangalore, India; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Jaipur, India; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Kochi, India; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Kolkata, India; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Mumbai, India; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

New Delhi, India; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Pune, India; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Vellore, India; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Haifa, Israel; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Kfar Saba, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Petah Tikva, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Rehovot, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Tel Aviv, Israel; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Tel Aviv, Israel; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Zerifin, Israel; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Bari, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Bologna, Italy; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Bologna, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Bologna, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Catania, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Chieti, Italy; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Chieti, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Ferrara, Italy; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Ferrara, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Firenze, Italy; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Firenze, Italy; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Genova, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Napoli, Italy; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Napoli, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Napoli, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Orbassano, Italy; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Orbassano, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Parma, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Pavia, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Perugia, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Pisa, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Pordenone, Italy; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Pordenone, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Roma, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

San Giovanni Rotondo, Italy; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

San Giovanni Rotondo, Italy; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Udine, Italy; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Udine, Italy; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Verona, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Pancreatic Cancer.

Riga, Latvia; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Kaunas, Lithuania; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Vilnius, Lithuania; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Vilnius, Lithuania; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Vilnius Lt, Lithuania; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Vilnius Lt, Lithuania; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Kuala Lumpur, Malaysia; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Penang, Malaysia; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Mexico City, Mexico; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Mexico City, Mexico; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Morelia, Mexico; Research Site:
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Tijuana, Mexico; Research Site:
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Amsterdam, Netherlands; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Auckland, New Zealand; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Christchurch, New Zealand; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Arequipa, Peru; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Chiclayo, Peru; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Lima, Peru; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Lima, Peru; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

San Isidro, Peru; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Gliwice, Poland; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Gliwice, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Lublin, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Poznan, Poland; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Szczecin, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Wroclaw, Poland; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Bucharest, Romania; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Cluj-Napoca, Romania; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Cluj-Napoca, Romania; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Craiova (Dolj County), Romania; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Iasi, Romania; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Sibiu, Romania; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Irkutsk, Russian Federation; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Kazan, Russian Federation; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Krasnodar, Russian Federation; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Moscow, Russian Federation; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

St Petersburg, Russian Federation; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Singapore, Singapore; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Singapore, Singapore; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Singapore, Singapore; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Ljubljana, Slovenia; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Pretoria, South Africa; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Alcorcon, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Alcoy, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Alicante, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Barcelona, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Barcelona, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Córdoba, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

El Palmar Murcia, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Elche, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Elche, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Girona, Spain; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Girona, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Granada, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Guadalajara, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Jaen, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

La Coruna, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Lleida, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Lugo, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Madrid, Spain; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Madrid, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Madrid, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Manresa, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Murcia, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Navarra, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Palma de Mallorca, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Pontevedra, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Sabadell, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Sagunto, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Santander, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Santander, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Sevilla, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Valencia, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Valencia, Spain; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Zaragoza, Spain; Research Site:
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship between Skin Toxicity and Survival

Stockholm, Sweden; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Kueishan, Taiwan; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Taipei, Taiwan; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Taipei, Taiwan; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Taipei, Taiwan; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Glasgow, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Leicester, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

London, United Kingdom; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

London, United Kingdom; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

London, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Manchester, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Northwood, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Southampton, United Kingdom; Research Site:
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Sutton, United Kingdom; Research Site:
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Sutton, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Truro, United Kingdom; Research Site:
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer